Evidence map›Paper›PMID 41524714›Full record

ReviewSmall (Weinheim an der Bergstrasse, Germany)2026

Next Generation Experimental Models of Venous Physiology and Pathology: Examining Human Relevance in Recapitulating Lower Extremity Flow and Valve Function in New Approach Methods (NAMs).

Sreelakshmy Suresh, Rana Dhar, Colin E Evans, Mark Hoofnagle, Abhishek Jain

Abstract readReview
In one paragraph

Review in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sreelakshmy SureshDepartment of Biomedical Engineering, Texas A&M College of Engineering, College Station, Texas, USA.
Rana DharCardiovascular Translational Research Center, University of South Carolina School of Medicine, Columbia, South Carolina, USA.
Colin E EvansCardiovascular Translational Research Center, University of South Carolina School of Medicine, Columbia, South Carolina, USA.
Mark HoofnagleDepartment of Surgery, Washington University in St Louis School of Medicine, St Louis, Missouri, USA.
Abhishek JainDepartment of Biomedical Engineering, Texas A&M College of Engineering, College Station, Texas, USA.ORCID https://orcid.org/0000-0003-2235-5139

Funding

Determinants of COVID19-induced venous thrombosis and targeted therapy assessed with bioengineered vein-chipR01HL157790 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI CONNOR, JOHN H, COOKE, JOHN P · 2021 to 2024
$2.8M
NASA 80ARC023CA002NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH R21DE035321NHLBI NIH HHS R01 HL157790NHLBI NIH HHS R01HL157790NSF CAREER 1944322U.S. Army Medical Research Acquisition Activity HT94252410432
6 · The paper itself

Abstract

Venous return depends on compliant vessels, competent valves, and auxiliary pumps such as the calf and thoracic muscles. Disruption of these mechanisms, through immobility, valve dysfunction, or inflammation, creates disturbed flow and heterogeneous shear that drive venous dysfunction and disease progression. Traditional animal models, though informative, fail to replicate human venous geometry and hemodynamics. This review critically evaluates current in vitro and in silico venous models, highlighting their capabilities and limitations in reproducing physiological flow, endothelial responses, and thrombus dynamics. By systematically comparing design parameters, cellular configurations, and flow regimes, we identify key gaps limiting the translational relevance of current NAMs. Building on this analysis, we propose future directions emphasizing hybrid patient-specific modeling, where imaging-derived geometries and digital twins are integrated with venous NAMs to capture individualized hemodynamics and immune-endothelial interactions. We further outline validation strategies linking NAM outputs with clinical and animal benchmarks to establish predictive fidelity. Together, these perspectives position venous NAMs as next-Generation tools to mechanistically dissect thrombosis, advance personalized risk assessment, and accelerate the development of targeted venous therapeutics.

Indexed as

Lower ExtremityVeinsVenous ValvesAnimalsHemodynamicsHumansdeep vein thrombosismicro physiological systemsnew approach methodsorgans‐on‐chipsvein‐chipsvenous physiology

Identifiers

PMID41524714
PMCPMC13592031

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.